The combination of thrombolytic therapy and recombinant tissue plasminogen activator (r-tPA) is safer than the application of r-tPA alone and decreases the risk of intracranial hemorrhage (Ren et al., 2012). This evidence concerns the gene PLAT and intracranial hemorrhage.